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Abstract
Background: Thyroid nodules are common but only a minority are malignant. Molecular testing can assist in
helping determine whether indeterminate nodules are suspicious for malignancy or benign. The objective of the
study was to determine if the analysis of mutations (BRAF, NRAS, KRAS and HRAS) using readily available molecular
techniques can help better classify indeterminate thyroid nodules.
Methods: A retrospective cohort of consecutive patients undergoing diagnostic thyroid surgery were analyzed for
the presence or absence of specific mutations known to be associated with thyroid malignancy in FNA samples.
Markers chosen were BRAF, NRAS, KRAS and HRAS. All were locally available and currently in use at our centre for
other clinical indications. Results from the molecular analysis were then compared to the histopathology from
thyroidectomy specimens to determine the sensitivity and specificity of these molecular techniques to classify
indeterminate thyroid nodules.
Results: Sixty consecutive patients with indeterminate FNAs were recruited. Twenty-three patients had malignant
tumors while 37 specimens were benign. Multiple different mutations were identified in the FNA samples. Overall
18 cases had a positive mutation (10 malignant and 8 benign). The sensitivity of BRAF, HRAS, KRAS, and NRAS was
8.7, 8.7, 8.7, and 17.4 respectively while the specificity was100, 83.7, 100 and 94.6.
Conclusion: While molecular analysis remains promising, it requires further refinement. Several markers showed
promise as good "rule-in" tests.
Background
The overall incidence of thyroid nodules in the general
public is estimated to be between 20-75 % [1]. A minor-
ity of these nodules are malignant. The standard work-
up for thyroid nodules includes a thyroid stimulating
hormone level, an ultrasound, and a fine needle aspir-
ation biopsy (FNAB). After completion of this standard
work-up, about 20 % of these remain indeterminate [2].
The proportion of malignancy in this group is around
20 % [3]. Further classification of these nodules may rely
on repeat FNAB, serial ultrasound follow-up, or diagnos-
tic thyroid surgery. These options are imperfect as
repeat FNAB is often unsuccessful at further classifying
these nodules, serial ultrasounds assume the small risk
of surveilling cancer, and diagnostic thyroid surgery is
invasive, has non-trivial risks and is often done for be-
nign disease. In addition, the uncertainty surrounding
indeterminate thyroid lesions can be a great consterna-
tion to patients [4].
Preoperative molecular analysis of the contents of FNA
has been an emerging field in thyroid research as it tries
to better classify thyroid nodules as benign or malignant.
Multiple mutations have been identified in thyroid cancer
and studied for their predictive ability in FNA specimens.
These include b-raf murine sarcoma viral oncogene
homolog B (BRAF), neuroblastoma RAS viral oncogene
homolog (NRAS), Kirsten rat sarcoma viral oncogene
homolog (KRAS), peroxisome, proliferator-activated re-
ceptor γ (PPARG), and the thyroid stimulating hormone
receptor gene (TSHR) among others [5–7].
Building on this previous work, novel molecular tests
such as, the Afirma Gene Expression Classifier and Thyro-
Seq v2 have been created [6, 8]. These molecular tests
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analyze specimen from FNAB simultaneously testing for
the presence of multiple mutations.
These molecular techniques are enormously promising.
Implementing highly accurate molecular assessments of
indeterminate thyroid lesions could lift patients and physi-
cians out of the miasma that is the indeterminate thyroid
nodule. Anxiety surrounding the diagnosis could be elimi-
nated, invasive surgery could be avoided and serial ultra-
sounds could be halted.
Unfortunately, in their current form the most sophisti-
cated and accurate molecular tests such as Afirma and
Thyroseq v2 are costly and, unavailable in Canada. Con-
sequently, our group decided to study the use molecular
markers that have been shown to be predictive of malig-
nancy in indeterminate samples and are already in use at
our institution. The hope of this study was that by creat-
ing a pragmatic assay of molecular markers we could re-
fine our diagnosis of indeterminate thyroid lesions.
The primary outcome of this pilot study was to assess
feasibility and if molecular testing could be conducted
based on the current infrastructure at our center. The
secondary outcomes were the sensitivity and specificity of
the tests to predict thyroid cancer and to determine the
proportion of cancer in indeterminate samples undergoing
recruitment.
Methods
A retrospective pilot study was conducted by reviewing
patient charts from the Head and Neck Clinics of four
Otolaryngology – Head & Neck Surgeons at St. Josephs
Healthcare Hamilton. Hamilton Integrated Research
Ethics Board (HIREB #12-3667) approval was obtained
prior to beginning the study. Records spanning the
period of August 2007 to July 2012 were examined for
all patients who had a thyroid FNAB with indeterminate
cytology. Indeterminate cytology comprises 3 recognized
Bethesda diagnostic categories: atypia or follicular lesion
of undetermined significance (AUS/FLUS), follicular
neoplasm or suspicious for follicular neoplasm (FN/
SFN). The inclusion criteria were patients who had
thyroid FNA with indeterminate cytology, a final surgical
excision diagnosis, were older than 18 years of age and
had moderate to good cellularity on FNA. Exclusion cri-
teria included patients with a family history of thyroid
cancer, history of radiation exposure and those who did
not have a final surgical excision diagnosis. A minimum
sample size of 220 was calculated based upon published
values from previous studies of molecular testing in thy-
roid cancer. A sample size of 60 was used for this feasi-
bility study. Using values of a sensitivity of 60 %, a
specificity of 92 %, and a prevalence of carcinoma in
indeterminate FNA results as 20 %, and a desired preci-
sion of 15 %, the sample size was calculated to be 60.
Once patients were identified who satisfied the inclusion
and exclusion criteria their cytology slides and cell
blocks were reviewed for cellularity and sample
adequacy i.e. thyroid follicle cells present, not just blood,
colloid and/or inflammatory cells. A tissue section was
cut from each cell block, stained with H&E, and exam-
ined to confirm cellularity. Two independent assessors
(pathologist and pathology resident) who were blinded
to both the FNA and final excisional diagnoses examined
each case. Those cases that had adequate cellularity (de-
fined as presence of thyroid follicle cells) were included
in the study.
Molecular analysis
A 7 μm tissue curl was cut from each cell block and
treated with TrimGen WaxFree™ DNA extraction kit for
formalin-fixed paraffin embedded tissue. Molecular ana-
lysis was conducted for oncogenes using polymerase
chain reaction (PCR) and pyrosequencing (Qiagen):
BRAF codon V600 mutations: V600E/K/D/R, KRAS
codons 12/13 mutations: G12A/D/R/C/S/V, G13D,
NRAS codon 61 mutations: Q61R/K/L/H/P/E/Q and
HRAS codon 61 mutations: Q61R/K/L/H/P. These were
then compared to the result of the final surgical speci-
men [5–7, 9–12]. These were used as they were cur-
rently available at our institution and being used
clinically for other purposes.
Results
Sixty patients were identified in the retrospective chart
review who met the inclusion and exclusion criteria. The
FNA samples were sent for molecular analysis for muta-
tions in BRAF, KRAS, NRAS and HRAS. It was feasible
to run all testing locally. Overall, of the 60 patients who
had indeterminate results on FNA, 37 (62 %) were be-
nign lesions while 23 (38 %) had malignant lesions when
the final surgical specimens were analyzed. The most
common benign entity was follicular adenoma while the
most common malignant entity was papillary carcinoma,
classical variant (Table 1). There were 2 patients who
had mutations in BRAF, 8 patients who had mutations
in HRAS, 2 patients who had mutations in KRAS and 6
patients who had mutations in NRAS. Overall there
were 18 mutations that were identified in the 60 patients
of this study. Of these 10 ended up being malignant and
8 ended up having benign pathology. BRAF had a speci-
ficity of 8.7 %, a sensitivity of 100 %, a positive predictive
value of 100 % and a negative predictive value of 63.8 %.
HRAS had a specificity of 8.7 %, a sensitivity of 83.7 %, a
positive predictive value of 25 % and a negative predict-
ive value of 59.6 %. KRAS had a specificity of 8.7 %, a
sensitivity of 100 %, a positive predictive value of 100 %
and a negative predictive value of 63.8 %. NRAS had a
specificity of 17.4 %, a sensitivity of 94.6 %, a positive
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predictive value of 66.7 % and a negative predictive value
of 64.8 %. Overall the combined specificity was 43.5 %,
the sensitivity was 78.4 %, a positive predictive value of
55.5 % and a negative predictive value of 69 % (Table 2).
Discussion
The primary outcome was to determine if it was feasible
to run molecular testing at our center with current re-
sources. It was determined that testing could be done lo-
cally at our center and results were obtained in a timely
fashion. There have been various studies illustrating the
effectiveness of Afirma and ThyroSeq v2 to determine
whether indeterminate lesions are benign or malignancy.
While both are effective testing modalities, their high
costs make it difficult to institute on a daily basis and
they are both not currently available in Canada. The
Afirma testing modality looks at the mRNA expression
of 167 genes and the ThyroSeq v2 looks at 13 genes and
for 42 types of gene fusions that occur in thyroid cancer.
This study was designed to be much simpler and as such
looked at only looked at 4 molecular genes. Afirma has a
published sensitivity of 92 %, a specificity of 52 % and a
negative predictive value of greater than 90 %. The Thyr-
oSeq v2 has shown a sensitivity of 90 %, a specificity of
93 %, a positive predictive value of 83 % and a negative
predictive value of 96 % [6, 8]. Overall the combined
specificity was 43.5 %, the sensitivity was 78.4 %, the
positive predictive value was 55.5 % and the negative
predictive value was 69 % for the four genes that were
looked at in this study. There was a great deal of vari-
ability in the markers themselves in this study with sen-
sitivity varying from 8.7 % to 17.4 % and specificity
varying from 83.7 % to 100 %.
Although this study did not approach the values for
sensitivity and specificity seen in studies on Afirma and
ThyroSeg v2, a few of the tests were useful if the test
was positive. This suggests that perhaps a relatively sim-
pler set of genetic tests could be created as a rule-in test.
This study was a feasibility study. Certainly any results
from this study require further refinement. As it was pri-
marily a feasibility study, the molecular analysis that was
conducted was done with genes that were already looked
at our center for other clinical indications and not prese-
lected for their effectiveness at determining thyroid can-
cer. There was no other reason as to why these
collective genes were chosen besides being convenient
and cost saving. Obviously, the construction of a more
complete molecular test requires inclusion of mutation
testing beyond what is readily available at our institution.
It seems that that combination of mutations could hold
promise in helping determine which patients have be-
nign nodules and which ones are suspicious for malig-
nancy. It has the ability to provide additional
information to patients when they are making decisions
on how to proceed with an indeterminate thyroid nod-
ule. Moreover, it has the potential to reduce the number
of diagnostic hemithyroidectomies which are invasive,
costly, anxiety provoking, and like all surgical proce-
dures; they have associated risks of complications. Thus,
even though there were limitations of this study it still
can be promising in providing patients with additional
information. It is unclear how effective this set of four
genes will be in terms of trying to delineate which thy-
roid nodules are benign and which ones are malignant.
One of the secondary outcome was the proportion of
malignancy in the sample of 60 indeterminate FNAs.
The proportion of malignancy in any sample depends on
many site specific factors. In this study, 38 % of these
lesions were malignant. This prevalence compares
favourably with the literature as values of roughly
Table 1 Histological analysis of final specimens
Benign Malignant
Nodular/adenomatous hyperplasia 7 (12 %) Papillary carcinoma, classical variant 9 (15 %)
Adenomatous colloid nodule 8 (13 %) Papillary carcinoma, follicular variant 7 (12 %)
Hurthle cell adenoma 1 (2 %) Papillary carcinoma, microcarcinoma variant 5 (8 %)
Follicular adenoma 17 (28 %) Papillary carcinoma, oncocytic variant 1 (2 %)
Atypical follicular adenoma 4 (7 %) Poorly differentiated follicular carcinoma 1 (2 %)
Total 37 (62 %) Total 23 (38 %)
Table 2 Sensitivity, specificity, positive and negative predictive value of each gene
Molecular Mutation Number of Positive Cases Malignant Benign Sp Sn PPV NPV
BRAF 2 2 0 8.7 100 100 63.8
HRAS 8 2 6 8.7 83.7 25 59.6
KRAS 2 2 0 8.7 100 100 63.8
NRAS 6 4 2 17.4 94.6 66.7 64.8
Overall 18 10 8 43.5 78.4 55.5 69
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15-30 % of indeterminate lesions are malignant are
reported in the literature [6]. The slightly higher rate of
malignancy raises the question of external validity of the
findings. However, concerns of this nature can be allayed
by the fact that the prevalence was only slightly different
and the fact that the sensitivity and specificity of a test is
independent of the prevalence in a population.
There are several limitations to this study. It is import-
ant to note that a pragmatic cohort was taken in this
pilot study. We do recognize the limitations of this and
a more generalizable cohort would be more applicable
in determining the sensitivity and specificity of such
tests in a clinical setting. Being a pilot study we limited
the cohort to patients who underwent surgery. More-
over, economic analysis and evaluation was not
completed in this pilot study as it was deemed not rea-
sonable as we are in the process of determining the effi-
cacy and effectiveness of such analysis. The small sample
size is a limitation of the study and the true sensitivity
and specificity of these combinations of markers will re-
quire a larger sample size. It is clear that larger samples
sizes are needed to determine if these clinical markers
will have an impact on the management of patients with
indeterminate thyroid nodules. These clinical markers
can aid in providing patients more information when
making decisions but it is unclear the impact these four
markers will have in changing the recommendations of
management.
The study illustrates the promise in potentially finding
a more convenient way to complete molecular analysis
on thyroid nodules with local resources. Moreover, with
the expansions in genetic thyroid research molecular
testing has the potential to change clinical practice for
patients suffering from thyroid nodules. The molecular
analysis of FNA specimens remains in its infancy. It is
likely though, that over the next several years more
molecular tests will become available and will become
integrated into clinical practice. Which tests are chosen
and how they are integrated into practice will certainly
be among the most important decisions facing thyroid
surgery in the coming years.
Conclusions
Overall there may be some benefit in the use of locally
available molecular analysis and testing in determining
malignancy in thyroid nodules. Despite a limited sample
size, molecular testing remains promising even with this
limited group of four genes.
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